CNBC March 24, 2025
Key Points
– Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year.
– The trial results are among the pharmaceutical industry’s most critical of the year, as they will bring Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
– The pill could potentially help broaden access for patients in the U.S. and internationally and alleviate the supply constraints that have plagued the injections on the market.
– Orforglipron could also help Eli Lilly solidify its dominance in the booming weight loss drug market as a slate of other drugmakers race to join.
Patients, doctors and investors...
Today's Sponsors
Today's Sponsor